PPIs Linked to Worse Outcomes With Widely Used Breast Cancer Drug
(MedPage Today) -- Using proton pump inhibitors (PPIs) during treatment with palbociclib (Ibrance) was linked to higher risks of progression and death among patients with breast cancer, according to a retrospective cohort study from South Korea...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Gastroenterology | Proton Pump Inhibitors PPIs | South Korea Health | Study